Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Autologous stem cell transplantation for acute myeloid leukemia

Bone Marrow Transplantation volume 31, pages 731–738 (2003)Cite this article

Summary:

Autologous bone marrow transplant (ABMT) and stem cell transplantation (ASCT) are important treatment modalities for acute myeloid leukemia (AML). The role of ASCT in first remission patients remains controversial. Phase II and phase III studies demonstrate that patients with favorable-risk cytogenetics benefit from ASCT, with reduction in relapse and improvement in leukemia-free survival (LFS). Patients with poor-risk cytogenetics do not appear to benefit significantly from ASCT and should preferentially be treated with allogeneic transplant. The role of ASCT for patients with intermediate risk disease is uncertain. It appears that ASCT in first remission will improve disease-free survival compared to standard chemotherapy. Sufficient patients who relapse after chemotherapy treatment can be salvaged with ASCT in second remission such that the beneficial effect on overall survival is blunted. ASCT produces equivalent results to ABMT but with reduced morbidity. The collection of stem cells during recovery from intensive dose consolidation therapy appears to be an attractive strategy that can increase the percentage of patients who are able to receive their intended transplant. Consolidation therapy prior to stem cell collection and transplant has been shown to decrease the relapse rate and improve outcomes, but the optimal nature of this consolidation therapy is unknown. For patients with AML in second remission, ABMT/ASCT offers a substantial salvage rate, and is particularly effective for patients with acute promyelocytic leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Gorin NC . Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073–1090.

    CAS  PubMed  Google Scholar 

  2. Cassileth PA, Anderson J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993; 11: 314–319.

    Article  CAS  PubMed  Google Scholar 

  3. Sanz MA, de la Rubia J, Sanz GF et al. Busulfan plus cyclophosphamide followed by autologous blood stem cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11: 1661–1667.

    Article  CAS  PubMed  Google Scholar 

  4. Labopin M, Gorin NC . Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. Leukemia 1992; 6 (Suppl. 2): 95–99.

    PubMed  Google Scholar 

  5. Gorin NC, Labopin M, Fouillard L et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 18: 111–117.

    CAS  PubMed  Google Scholar 

  6. Linker CA, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 2: 311–318.

    Google Scholar 

  7. Linker CA, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 1998; 22: 856–872.

    Article  Google Scholar 

  8. Damon LE, Rugh HS, Ries CA et al. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transplant 1996; 17: 93–99.

    CAS  PubMed  Google Scholar 

  9. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  10. Burnett AK, Goldstone AH, Stevens RMF et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700–708.

    Article  CAS  PubMed  Google Scholar 

  11. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1666.

    Article  CAS  PubMed  Google Scholar 

  12. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  13. Korbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (PBMT) in standard risk AML: influence of source and cell composition of the autograft on hematopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343–349.

    CAS  PubMed  Google Scholar 

  14. Stein AS, O'Donnell MR, Chai A et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14: 2206–2216.

    Article  CAS  PubMed  Google Scholar 

  15. Stein A, O'Donnell, Parker P et al. Interleukin-2 (IL-2) post high dose cytarabine mobilizes autologous stem cell transplant (ASCT) for adult patients with acute myelogenous leukemia (AML) in first complete remission. Blood 1998; 92 (Suppl. 1): 292a (Abstr. 1196).

    Google Scholar 

  16. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997; 20: 821–826.

    Article  CAS  PubMed  Google Scholar 

  17. Demirer T, Buckner CD, Appelbaum FR et al. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995; 15: 915–922.

    CAS  PubMed  Google Scholar 

  18. Visani G, Lemoli RM, Tosi P et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant 1999; 24: 467–472.

    Article  CAS  PubMed  Google Scholar 

  19. Reiffers J, Labopin M, Sanz M et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 2000; 25: 1115–1119.

    Article  CAS  PubMed  Google Scholar 

  20. de Witte T, Keating S, Suciu S et al. A randomized comparison of the value of autologous BMT versus autologous PSCT for patients with AML in first CR in the AML 10 trial of the EORTC LCG and GIMEMA. Blood 2001; 98 (Suppl. 1): 859a (Abstr. 3565).

    Google Scholar 

  21. Linker CA, Ries CA, Damon LE et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000; 6: 50–57.

    Article  CAS  PubMed  Google Scholar 

  22. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  23. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype1. Cancer Res 1998; 58: 4173–4179.

    CAS  PubMed  Google Scholar 

  24. Heil G, Krauter J, Kirchner H et al. Risk adapted induction and consolidation therapy including autologous peripheral blood stem cell transplantation (PBSCT) in adults with de novo AML aged ⩽60 years. Blood 2000; 96 (Suppl. 1): 322a (Abstr. 1392).

    Google Scholar 

  25. Sanz MA, Arcese W, de la Rubia J et al. Stem cell transplantation for (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: a survey of the European Blood and Marrow Transplant group. Blood 2000; 96 (Suppl. 1): 522a (Abstr. 2247).

    Google Scholar 

  26. Mehta J, Powles R, Sirhohi B et al. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes. Blood 2001; 98 (Suppl. 1): 716a (Abstr. 2993).

    Google Scholar 

  27. Taniguchi S, Gondo H, Hayashi S et al. Autologous blood stem cell transplantation conditioned with granulocyte-colony stimulating factor combined preparative regiment for acute myeloblastic leukemia in first remission. Blood 2001; 98 (Suppl. 1): 690a (Abstr. 2884).

    Google Scholar 

  28. Vey N, Stoppa AM, Faucher C et al. Autologous stem cell transplantation (ASCT) for acute myelogenous leukemia (AML) in first complete remission (CR): a retrospective single center analysis of 101 patients. Blood 1999; 94 (Suppl. 1): 579a (Abstr. 2583).

    Google Scholar 

  29. Stein AS, O'Donnell MR, Slovak ML et al. Does high dose cytarabine/idarubicin induction followed by autologous stem cell transplant improve survival in adult acute myelogenous leukemia patients with good risk cytogenetics? Blood 2001; 98 (Suppl. 1): 690a (Abstr. 2886).

    Google Scholar 

  30. Ehninger G, Schakel U, Soucek S et al. Autologous peripheral blood stem cell transplantation in de novo AML patients <60 year with intermediate risk cytogenetics. Blood 2000; 96 (Suppl. 1): 843a (Abstr. 3643).

    Google Scholar 

  31. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–1614.

    CAS  PubMed  Google Scholar 

  32. Mehta J, Powles R, Singhal S et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. BMT 1995; 16: 499–506.

    CAS  Google Scholar 

  33. Sirohi B, Powles R, Singhal S et al. The impact of consolidation chemotherapy on the outcome of autotransplantation for acute myeloid leukemia in first remission : single center experience of 118 adult patients. Blood 2001; 98 (Suppl. 1): 690a (Abstr. 2885).

    Google Scholar 

  34. Tallman MS, Perez W, Keating A et al. Pretransplant consolidation chemotherapy decreases leukemia relapse after autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML) in first complete remission (CR). Blood 2001; 98 (Suppl. 1): 859a (Abstr. 3566).

    Google Scholar 

  35. Meloni G, De Fabritiis P, Petti MC et al. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282–2285.

    CAS  PubMed  Google Scholar 

  36. Meloni G, Vignetti M, Avvisati G et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 1996; 18: 693–698.

    CAS  PubMed  Google Scholar 

  37. Lioure B, Witz F, Deconninck E et al. Autologous stem cell transplantation (ASCT) represents the best consolidation therapy for acute myelogenous leukemia (AML) in second complete remission (CR): a retrospective study of the GOELAMS group. Blood 1997; 90 (Suppl. 1): 384a (Abstr. 1710).

    Google Scholar 

  38. Califaretti N, Davidson M, Abraham R et al. Autologous bone marrow transplant (ABMT) for acute myelogenous leukemia (AML) in second or subsequent remission. Blood 1998; 92 (Suppl. 1): 294a (Abstr. 1203).

    Google Scholar 

  39. Linker CA, Damon LE, Ries CA et al. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 2002; 29: 297–301.

    Article  CAS  PubMed  Google Scholar 

  40. Linker C, George S, Hurd D et al. Autologous stem cell transplantation for acute myeloid leukemia in second remission-CALGB 9620. Blood 2001; 98 (Suppl. 1): 689a (Abstr. 2881).

    Google Scholar 

  41. Nabhan C, Mehta J, Tallman MS . The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 2001; 28: 219–226.

    Article  CAS  PubMed  Google Scholar 

  42. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000; 14: 1006–1013.

    Article  CAS  PubMed  Google Scholar 

  43. Roman J, Martin C, Torres A et al. Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 1997; 19: 679–683.

    Article  CAS  PubMed  Google Scholar 

  44. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood 1997; 90: 1321–1325.

    CAS  PubMed  Google Scholar 

  45. de la Rubia J, Sanz GF, Martin G et al. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant 1996; 18: 1167–1173.

    CAS  PubMed  Google Scholar 

  46. Ringden O, Labopin M, Frassoni F et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplant 1999; 24: 389–396.

    Article  CAS  PubMed  Google Scholar 

  47. Laporte J, Douay L, Lopez M et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810–3818.

    CAS  PubMed  Google Scholar 

  48. Miller CB, Rowlings PA, Zhang M et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001; 29: 1336–1346.

    Article  CAS  PubMed  Google Scholar 

  49. Fauth F, Martin H, Sonnhoff S et al. Purging of G-CSF mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells. Bone Marrow Transplant 2000; 25: 831–836.

    Article  CAS  PubMed  Google Scholar 

  50. Ball ED, Wilson J, Phelps V et al. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up. Bone Marrow Transplant 2000; 25: 823–829.

    Article  CAS  PubMed  Google Scholar 

  51. Margolin KA, van Besien K, Wright C et al. interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant 1999; 5: 36–45.

    Article  CAS  PubMed  Google Scholar 

  52. Schiller G, Wong S, Lowe T et al. Autologous transplantation of peripheral blood progenitor cells for adults with acute myelogenous leukemia in first complete remission: the impact of interleukin-2 mobilization and maintenance on leukemia-free survival. Blood 2000; 96 (Suppl. 1): 427a (Abstr. 1834).

    Google Scholar 

  53. Hogge D, Eaves C, Barnett M et al. Autologous stem cell transplants (ASCT) cultured in interleukin-2 (IL-2) for high risk acute myelogenous leukemia (AML) in first complete remission (CR). Blood 1998; 92 (Suppl. 1): 292a (Abstr. 1195).

    Google Scholar 

  54. Kolitz JE, George SL, Dodge RK et al. Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia (AML) <60 years in first complete remission (CR): results of CALGB 9621. Blood 2001; 98 (Suppl. 1): 688a (Abstr. 2879).

    Google Scholar 

  55. Simonsson B, Totterman T, Hokland P et al. Roquinimex (linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1121–1127.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of California, San Francisco, CA, USA

    C A Linker

Authors
  1. C A Linker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linker, C. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 31, 731–738 (2003). https://doi.org/10.1038/sj.bmt.1704020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704020

Keywords

This article is cited by

Search

Advanced search

Quick links